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Abstract
We provide evidence for the presence of cannabinoid CB2 receptors in some cellular types
of the cochlea of the adult albino rat. Cannabinoids and their receptors are increasingly
being studied because of their high potential for clinical use. As a hyperspecialized portion
of the peripheral nervous system, study of the expression and function of cannabinoid
receptors in the hearing organ is of high interest. Stria vascularis and inner hair cells
express CB2 receptor, as well as neurites and cell bodies of the spiral ganglion. Cellular
types such as supporting cells and outer hair cells, in which the expression of other types of
functional receptors has been reported, do not significantly express CB2 receptors in this
study. An up-regulation of CB2 gene expression was detected after an ototoxic event such
as cisplatin treatment, probably due to pro-inflammatory events triggered by the drug. That
fact suggests promising potential of CB2 receptor as a therapeutic target for new treatments
to palliate cisplatin-induced hearing loss and other ototoxic events which triggers inflamma-
tory pathways.
Introduction
There is an increasing body of research on molecular signalling in the cochlea with the expecta-
tion that a deeper understanding of cell damage and regeneration pathways could uncover
potential targets for the treatment and prevention of auditory damage.
In the context of searching for potential therapeutic targets against inner ear disorders, the
study of cannabinoid receptors expression in the auditory organ is of great interest. Cannabi-
noid receptors modulate a large number of normal brain and bodily functions and have been
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implicated as potential drug targets in a wide variety of diseases from cancer [1] to neurodegen-
erative disorders [2].
The endocannabinoid system is increasingly being studied because of the high potential for
clinical use of cannabinoids. The endocannabinoid system is a cell communication system
which consists of two receptors, CB1 and CB2, their endogenous ligands (anandamide and
2-AG), and the enzymes that produce and metabolize these ligands [3]. Cannabinoids exert a
wide spectrum of therapeutic effects through CB1 and CB2 receptors [4]. Cannabinoid recep-
tors are of a class of cell membrane receptors under the G protein-coupled receptor superfam-
ily that contain seven transmembrane spanning domains [3]. Also, the existence of other
cannabinoid receptors is suspected due to the actions of compounds that produce cannabi-
noid-like effects without activating either CB1 or CB2 [5]. CB receptors signaling pathways
include regulation of adenylyl cyclase, MAP kinase, intracellular Ca 2+, and ion channels [6].
The first cannabinoid receptor (CB1) was characterized in rat brain in 1988 [7] and is mainly
expressed in lung [8], liver [9] and kidneys [10]. CB2 was isolated in the rat spleen in 1993 [11].
CB2 receptor has been found to be 10–100 times more abundant than CB1 in immune cells
such as macrophages, B cells, “natural killer” (NK) cells, monocytes, neutrophills and T cells
[12]. It has also been described in non-immunological cells such as gastrointestinal system cells
[13]; lung endotelium [14]; osteocytes and osteoclasts of bone [15] mouse spermatogenesis
[16] and other aspects of reproduction [17]; in trabecular meshwork cells of the eye [18]; in
adipocytes [19]; and in cells from cirrhotic liver (but not in the healthy organ) [20].
Cisplatin (CDDP) was the first platinum-based drug to be used and nowadays is widely
employed in the treatment for some neoplastic entities such as head and neck, ovary, bladder,
lung or brain. However, it presents severe side effects such as nephrotoxicity, bone marrow tox-
icity, gastrointestinal toxicity, liver toxicity, peripheral nervous system toxicity and ototoxicity
[21]. Most of these related effects can be treated. However, CDDP- induced ototoxicity, that
implies several cochlear damage which evolves in hearing impairment, tinnitus and dizzines, is
one of the main reasons to chemotherapy discontinue.Inflammation has been recently shown
to play a role in auditory cells apoptosis induced by CDDP, and is the main mechanism
involved in immune-mediated hearing loss [22]. The inflammatory mediator inducible nitric
oxide synthase (iNOS), is activated through nuclear factor-kB (NF-kB) and is related with
cochlear wound by increasing cytokine expression and apoptosis in the cochlea [23]. Therefore,
CDDP induce an over expression of COX-2, iNOS and TNF-α, that are regulated in cell
nucleus by STAT1. STAT1 has an important role in inflammation and apoptosis in the cochlea
like Kaur et al. demonstrated when used short interfering RNA against STAT1 to ameliorate
CDDP-induced ototoxicity reducing the inflammation [24].
There is a report on the expression of CB2 receptors in the auditory HEI-OC1 (House Ear
Institute-Organ of Corti) cell line [25]. In this study, researchers were able to demonstrate that
JWH-015 (a synthetic CB2 agonist) could inhibit CDDP-induced apoptosis in HEI-OC1 cells.
Up to our knowledge, CB2 receptor has been studied in vivo in relation to inflammatory
processes in the outer ear [26] and the middle ear [27], but there are no reports on CB2 receptor
expression or function in the inner ear.
The aim of this study was to explore the expression of CB2 receptors in the mature inner ear
of the Wistar rat by means of immunohistochemical staining in post-mortem tissue sections of
the cochlea. CB2 gene expression was also measured by RT-qPCR in healthy and CDDP treated
animals, using a well-established murine model of CDDP-induced ototoxicity, in order to
study if an ototoxic event triggers an up- or down-transcriptional modulation of this receptor
in the cochlea. These results may have important preliminary implications for the therapy of
CDDP-induced hearing loss and other inflammatory inner ear diseases using CB2 receptor as a
therapeutic target to ameliorate ototoxicity events.
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Material and Methods
Animals
Thirty three female Wistar rats (14–16 weeks old) weighting between 200 and 280 g were used
in the present study. Animals were breaded and handled at the animal facility of the Health
Research Institute Puerta de Hierro in controlled temperature rooms, with light–dark cycles,
and with free access to food and water. Rats with signs of present of past middle ear infection
were discarded.
The animals were handled according to Spain Royal Law 53/2013 and the European Direc-
tive 2010/63/EU. The study was approved by the Clinical Research and Ethics Committee of
Hospital Universitario Puerta de Hierro and the Autonomic Community of Madrid (PROEX
022/16).
Auditory steady-state responses (ASSR)
The animals were randomly assigned in two different groups: one group (n = 20; 10 for histol-
ogy and 10 for RT-PCR analysis) was administered with phosphate buffered saline (PBS) as a
control, and the other group (n = 13; 3 for histology and 10 for RT-PCR) received 10 mg/kg of
CDDP (Accord Healthcare, Barcelona, Spain) dose. After 72 hours animals were euthanized by
CO inhalation and cochleae, spleen and kidneys of each animal were extracted. Animals were
anesthetized with intraperitoneal ketamine (100 mg/kg) and diazepam (0.1 mg/kg) before the
procedure.
Subcutaneous electrodes were placed over the vertex (active) and in the pinna of each ear
(reference). An insert earphone (Etymotic ER-2) was placed directly into the external auditory
canal. Ground electrodes were placed over the neck muscles. ASSR were recorded using an
evoked potential averaging system (Intelligent Hearing System Smart-EP, FL, USA) in an elec-
trically shielded, double-walled, sound-treated booth in response to 100 ms clicks or tone
bursts, at 8, 12, 16, 20, 24, 28 and 32 kHz with 10 ms plateau and 1 ms rise/fall time. Intensity
was expressed in decibels sound pressure level (dB SPL) peak equivalent. Intensity series were
recorded, and an ASSR threshold was defined by the lowest intensity able to induce a replicable
visual detectable response.
ASSR was measured before treatments with PBS or CDDP, and 72 hours after the
administration.
Tissue extraction, fixation and decalcification
Thirteen animals were euthanized by CO inhalation and subsequently decapitated. Temporal
bones were removed and structures of middle ear dissected for isolation of the cochlear por-
tion. Cochleae were fixed by intralabyrinthine perfusion with 4% paraformaldehyde (PFA) in
phosphate buffer (pH = 7) and then immersed for 24 hours in 4% PFA solution. Afterwards,
cochleae were decalcified in 0.12 M Ethylenediaminetetracetic acid dipotassium salt dihydrate
(Sigma-Aldrich, St.Louis, USA) for 7–10 days. Cochleae were finally maintained in 1% PFA in
0.1 M PBS.
Spleen and kidneys of each animal were extracted and submitted to the same protocol
(except the decalcification step).
Histological processing
In order to obtain complementary images from the cellular structures of the organ of Corti, the
two cochleae from one animal were each randomly processed by one of the following
techniques:
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Inner ear surface preparations. Cochleae were dissected following Liberman’s technique.
In short, cochlea was bisected along a mid-modiolar plane and the half-turns cut apart, ensur-
ing that the spiral ligament and tectorial membrane were pulled off and the resulting pieces of
tissue were mounted on a microscope slide for examination in a confocal laser scanning
microscope.
Mid-modiolar sections. The cochleae were processed for paraffin embedding. Careful
placement of the cochlear portion was performed to obtain transverse serial sections of 6 μm
(Leica microtome RM 2235), which were orthogonal and complementary to the surface
preparations.
Immunolabeling
CB2 receptors were immunostained with the polyclonal anti-cannabinoid receptor II antibody
(ab45942, Abcam, USA; dilution 1:50), using Alexa 488-conjugated anti-rabbit raised in goat
(Molecular Probes–Invitrogen; dilution 1:400) as the secondary antibody. Antibodies were
diluted in PBS supplemented with 1% bovine serum albumin (BSA) and 0.04% triton. All prep-
arations were contrasted with TOPRO-3 iodide (Life Technologies, USA; dilution 1:500). Spec-
ificity was confirmed in separated experiments with additional negative controls, including
tissue sections incubated with primary antibody pre-adsorbed to an excess of control peptide
(ab45941, Abcam, USA; dilution 1:25).
Cochleae assigned to surface preparations were immunolabeled once bisected into two
halves and before final dissection, by means of a “free floating” technique. Transversal sections
were immunolabeled once mounted on the slide and conveniently dried.
As a positive control of the primary antibody used, spleen and kidneys [28] of each animal
were submitted to the same protocol.
Microscopic analysis
Samples were visualized by means of a confocal laser scanning microscope Nikon Eclipse
C1 coupled to a Nikon 90i microscope with a camera DXM1200F (Nikon, Haarlem,
Netherlands).
For validation of the specificity of the CB2 immunolabelling, immunofluorescence patterns
were compared to negative controls in which primary antibody was pre-adsorbed with block-
ing peptide, and kidney and spleen were used as a positive control.
Measurement of immunofluorescence intensity
For relative quantification of CB2 fluorescence intensity, standardized settings for image acqui-
sition and processing were used. To obtain values for CB2 immunofluorescence intensity in cell
types of the cochlear duct, morphological boundaries of each cell type were determined on
phase contrast images. The cell type-specific outlines were plotted with the corresponding
grey-scaled CB2 immunofluorescence images. Single measurements of fluorescence intensity
were performed using ImageJ software (version 1.40 g; National Institutes of Health, US). CB2
fluorescence intensity values for each cell type of the cochlear duct were averaged from ten
independent measurements of immunolabelled cochlear mounts and sections from ten speci-
mens. The fluorescence intensity of CB2 labelling was plotted using arbitrary units ranging
from 0 to 2500.
Following the same protocol used to determine relative fluorescence intensity in cell types
of the cochlea, effect of CDDP treatment in the immunofluorescence was compared in stria
vascularis and IHC of three animals treated with CDDP and three animals treated with PBS.
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Measurement of CB2 gene expression by RT-qPCR in healthy and
CDDP treated animals
Total RNA purification. Dissected cochleae obtained from CDDP-treated and control
Wistar rats were embebed in RNA later overnight and kept at -80°C until purification. Tissues
were resuspended in Trizol and homogenized by the MagNA Lyser System (Roche). Total
RNA was isolated by RNeasy kit (QIAGEN) including on-column DNAse Digestion, following
protocol previously described [29].
RNA concentration was determined by spectrophotometry and each sample was reverse-
transcripted to cDNA by using the First-Strand cDNA Synthesis Protocol (Agilent
Technologies).
Relative Quantification of CB2 and CB1 gene expression. qPCR was performed in a
LC480 (Roche) in order to quantify CB2 and CB1 levels of gene expression in relation to the
level of the reference TATA-binding protein (TBP), in the cochlear tissue using Real Time
Ready Single Assay (TBP Transcript ID ENSRNOT0000002038, amplicon length of 75 bps
from 1029 to 110; CB2 Transcript ID ENSRNOT00000012342, amplicon length of 65 bps from
344 to 408; CB1 Transcipt ID ENSRNOT00000010850, amplicon length of 66 bps from 3244 to
3309; Roche). CB1 gene expression was used as a control (see S1 Fig).
Statistical analysis
Statistical analysis was performed with GraphPad Prism6 (San Diego, USA). One-way
ANOVA was used to analyze for statistical significance of the results. Tukey test was used to
identify significant differences between the paired treatments. p<0.05 was considered statisti-
cally significant.
Results
Ototoxic effect of CDDP-treatment
Post-treatment ASSR recordings were found to be higher than pre-treatment ASSR recordings
in the CDDP-treated animals, as it was previously described [30]. PBS-treated animals did not
suffer hearing loss (Fig 1).
CB2 receptor detection in the cochlea by immunohistochemistry
CB2 labeling was detected in the organ of Corti, specifically in inner hair cells (IHC) (Fig 2).
In the stria vascularis, the CB2 labeling pattern was mostly coincident with an intermediate
region within the stria vascularis, although some of the clearly immunolabeled cells occupied a
luminal position and also the basal region in some areas. This is compatible with the distribu-
tion of intermediate cells as well as at least some of the marginal and basal cells (Fig 3).
A strong CB2 labeling was also observed in the soma and neurites of the spiral ganglion neu-
rons (Fig 4).
As a control, the same protocol was assayed in the kidney and spleen. A strong marking was
observed in the spleen related to the B cells (Fig 5A). A strong labeling of CB2 receptor in the
epithelial cells of renal tubules was observed in the kidney. A slightly marking in the glomerule
was also detected and the pattern of staining was suggestive of podocyte labeling, as previously
described by Barutta et al. (Fig 5B). Tissue sections incubated with CB2 primary antibody pre-
adsorbed with control peptide did not show immunofluorescence, demonstrated the specificity
of primary antibody used against the CB2 receptor (S1 Fig).
Relative quantification of CB2 immunofluorescence labeling intensity in the IHC and OHC,
the stria vascularis, modiolus, Reissner and tectorial membranes and the supporting cells of the
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rat inner ear is presented in Fig 6. OHC as well as supporting cells were almost completely
devoid of CB2 staining. Relative immunofluorescence of OHC was remarkably lower when
compared to labeling of IHC and was not statistically significant (Fig 6). The same protocol
was assayed to compare relative fluorescence in in the stria vascularis (Fig 7A and 7B) and
IHC (Fig 7C and 7D) of healthy and CDDP-treated animals. CB2 immunofluoresce was higher
Fig 2. Detailed view of the sensory hair cells of the organ of Corti. Detailed view of the 3 rows of OHC (arrows) and the
single row of IHC (arrowhead). (A) Mid-modiolar section. (B) Cochlear whole mount. Immunofluorescence labeling of CB2
receptors is shown in green. To-Pro (blue) stains nuclei of cells. Intense fluorescence is observed in IHC (arrowhead), but
not in OHC. Labeling of nerve fibers can be seen at the bottom of the figure (FN). IHC: inner hair cell. OHC: outer hair cell.
(Scale bar = 30μm).
doi:10.1371/journal.pone.0161954.g002
Fig 1. Hearing thresholds before and after intraperitoneal administration of 10 mg/kg dose of CDDP or
PBS.CDDP-induced hearing loss was statistically significant for all frequencies with respect to pre-treatment
hearing. The diagrams include the mean, the standard deviation (n = 33), and the ANOVA results (difference
statistically significant respect tectorial membrane *p<0.05).
doi:10.1371/journal.pone.0161954.g001
CB2 Receptor Expression in the Cochlea of Adult Albino Rat
PLOS ONE | DOI:10.1371/journal.pone.0161954 August 26, 2016 6 / 15
in the stria vascularis of CDDP-treated animals in a statistically significant way (Fig 7E). No
difference between IHC of healthy and CDDP-treated animals was achieved.
CB2 gene expression in the cochlea and CDDP induced an up-
regulation in their expression
Gene expression of CB2 receptors was studied in the cochlea of healthy animals with respect to
TBP reference gene. The relative levels of expression showed up-transcriptional regulation of
CB2 under CDDP treatment in a statistically significant way. Similar results were observed in
kidney of animals untreated, an under CDDP treatment (Fig 8).
Level of CB1 gene expression in both organs was also measured as a control. CB1 receptors
expression was detected in the cochlea and in the kidney. A slightly down-transcriptional regu-
lation in the CDDP treated animals was observed in the cochlea, but there was no statistically
significant difference between control and CDDP-treated groups (see S2 Fig).
Discussion
The expression of cannabinoid receptors in a specific tissue opens the door to potential treat-
ments with agonists and antagonists that could trigger certain cell signaling pathways. Expres-
sion of CB2 has also been described in astrocytes and some neuron subpopulations. Role of
CB2 receptor in the central nervous system is related to neuroinflammation and
Fig 3. Image showing intense CB2 immunolabeling in cellular types of the stria vascularis (SV). Intermediate cells
are indicated by long arrow. Marginal cells (short arrows); basal cells (arrowheads) might show labeling at some points.
Fibrocytes of the spiral ligament (Fc) do not show expression of CB2 receptors. (Scale bar = 30μm)
doi:10.1371/journal.pone.0161954.g003
CB2 Receptor Expression in the Cochlea of Adult Albino Rat
PLOS ONE | DOI:10.1371/journal.pone.0161954 August 26, 2016 7 / 15
neurodegeneration [31]. In the peripheral nervous system, CB2 agonists have analgesic effects
by acting at dorsal root ganglia (as well as at spinal cord) [32]. Other authors have reported
CB2 expression on human skin nerve fibers [33]. Baek et al. previously described expression of
CB2 protein receptor in the vestibular and cochlear nuclei of the brain in a rat model, suggest-
ing that it could have an important role in the control of balance and hearing function [34]. As
part of the peripheral nervous system [35], it is not surprising to find such a remarkable immu-
nolabelling of CB2 receptor in organ of Corti cells, although its functional role has still to be
ascertained. Immunolabeling to CB2 receptor resulted to be higher in the stria vascular of ani-
mals which received the chemotherapeutic, but no difference could be appreciate in the IHC of
healthy and CDDP-treated animals. Due to these limitations of immunohistochemistry to
appreciate differences in the transcriptional up-regulation of CB2 between healthy and CDDP-
treated animals, which suffered big structural tissue degradation, RT-qPCR was assayed to
determine the regulation of CB2 gene expression.
Fig 4. Close view of CB2 immunolabeling of nerve fibers and spiral ganglion.Neurites are intensely labeled (short
arrows), as well as the soma (long arrow) of the spiral ganglion (SG) neurons (Scale bar = 30μm).
doi:10.1371/journal.pone.0161954.g004
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Fig 5. Detailed view of immunolabeling of CB2 in the spleen and the kidney.Detailed view of CB2
immunolabeling in the spleen (A), used as a positive control of the primary antibody (Scale bar = 100μm).
Detailed view of CB2 immunolabeling of epithelial cells of the renal tubules (RT) and the glomerule (G) of the
kidney (B). (Scale bar = 30μm).
doi:10.1371/journal.pone.0161954.g005
Fig 6. Relative quantification of CB2 immunofluorescence labeling intensity in different structures of
the cochlea by ImageJ. Support cells: supporting cells (including Deiters’, Hensen’s, Claudius and pillar
cells). Tectorial m: tectorial membrane (acellular). Reissner m.: Reissner membrane. OHC: outer hair cells.
IHC: inner hair cells. Relative immunofluorescence in the IHC and in the stria vascularis was significantly than
in the other cell types. The diagrams include the mean, the standard deviation (n = 10), and the ANOVA
results (difference statistically significant respect tectorial membrane *p<0.05).
doi:10.1371/journal.pone.0161954.g006
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In 2005 meeting of the Association for Research in Otolaryngology (ARO), Fauser et al.
reported preliminary studies of the expression of CB1 cannabinoid receptor in type I and type
II spiral ganglion cells that was higher after intratympanic treatment with salicilate and gluta-
mate in comparison with saline, with no specific stain in the organ of Corti or stria vascularis
[36]. In this study high values of CB1 gene expression was observed and used as a control of
cannabinoid gene expression (see S2 Fig), probably due to the presence of the spiral ganglion
in the dissected cochleae. A slightly down-regulation of CB1 gene expression in the cochlea and
in the kidney was observed when animals received CDDP treatment, being statistically signifi-
cant in the kidney probably due to a primary down-regulation trying to ameliorate tissue dam-
age promoted by CB1 in nephropathy models [37]. Recent studies go deeper in the role of CB1
Fig 7. Relative quantification of CB2 immunofluorescence labeling intensity in healthy and CDDP-
treated animals by ImageJ.Detailed view of the stria vascularis (SV) and the IHC (arrowhead) of healthy (A
and C) and CDDP-treated animals (B and D) (Scale bar = 100μm). Relative immunofluorescence in the IHC
and in the stria vascularis of healthy and CDDP-treated animals (E). CB2 relative immunofluorescence was
significantly higher only in the stria vascularis of animals treated with CDDP if compared with the control
group. The diagram include the mean, the standard deviation (n = 6; 3 control and 3 CDDP-treated), and the
ANOVA results (difference statistically significant in each cellular structure between healthy and CDDP-
treated animals *p<0.05).
doi:10.1371/journal.pone.0161954.g007
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receptor in hearing function. Zheng et al. use CBD and Δ-9-THC, and concluded that their
results suggest that cannabinoids, such as Δ-9-THC and CBD, may actually aggravate tinnitus,
probably because of the net effect of activation of CB1 receptors in the dorsal cochlear nucleus
might be to increase the excitation of fusiform cells, thus exacerbating neuronal hyperactivity
[38]. In a study published in Hearing Research, researchers showed in knockout CB1 mice, the
role of the cannabinoid receptor in hearing. Animals without CB1 presents deficit in their
audiograms for frequencies above 8 kHz, but they are still able to distinguished changes in fre-
quencies as well as the wild type [39].
Up to our knowledge, this is the first in vivo report of the expression of CB2 receptors in the
inner ear of mammals. Expression of CB2 gene had been previously described in the in vitro
line HEI-OC1, by means of RT-qPCR [25]. The authors demonstrated that JWH-015 (a syn-
thetic CB2 agonist) and HU210 (CB1 agonist), could inhibit CDDP-induced apoptosis in
HEI-OC1 cells. Specifically, they found that JWH-015 inhibited CDDP-induced caspase-3 and
caspase-8 activity; cytochrome c (proapoptotic molecule) release from the mitochondria;
increased phosphorylation of ERK; blocked the increase of ROS produced by CDDP; and
inhibited TNF-α production on HEI-OC1 cells. From this, they suggested that CB activation
was important in CDDP-induced apoptosis of HEI-OC1 cells.
HEI-OC1 cells express several molecular markers characteristic of organ of Corti sensory
cells and could be considered as precursors. CB2 immunolabeling in our study was seen in
inner hair cells, but not in outer hair cells. Previous studies suggested that hair cell types
derived from different progenitor cells. Specifically, these studies suggest that IHC derive from
Fig 8. Measure of relative CB2 gene expression by RT-qPCR.Measure of CB2 gene expression in the
cochlea and kidney of healthy (control) and CDDP treated animals, respect TBP reference. CB2 gene
expression was significantly higher in animals treated with CDDP than those in control group. The diagrams
include the mean, the standard deviation (n = 10), and the ANOVA results (difference statistically significant
respect control *p<0.05).
doi:10.1371/journal.pone.0161954.g008
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the greater epithelial ridge and the OHC derive from the lesser epithelial ridge [40, 41]. This
difference during ontogenesis has been related to the lateral process of inhibition that avoid
cells from follow the same developmental pathway [42]. These differences in the development
of IHC and OHC could explain the differential immunolabeling of CB2 receptor in sensory
cells reported in our assays.
Our study suggests the expression of CB2 receptor mostly in the intermediate region of the
stria vascularis, although luminal and basal labeling could also be seen. We consider this as a
limitation of our study and further studies would be needed to ascertain what cellular types are
specifically expressing CB2 receptor. Potential labeling of residual erythrocytes within the capil-
lary vessels of stria vascularis was contemplated, but we consider that it small size is negligible
in relation to strial cells. The fact that CB2 immunolabeling is also located in the stria vascularis
suggests that CB2 receptors might play a role in generation and/or maintenance of endoco-
chlear potential. Potential interaction with structures identified in stria vascularis that are
related to water and ion transport, antioxidant defenses and other homeostatic mechanisms
merit further research.
CDDP clinical use is limited due to the induced toxicity affecting nervous system, kidney
function and hearing. CDDP induces apoptosis by binding to DNA, ROS accumulation,
increased lipid peroxidation and Ca2+ influx and inflammation events [43]. In the present
study CDDP treated animals presents an up-regulation in the expression of CB2 gene in
cochleae and also in the kidney. Mukhopaday et al. used an agonist of CB2 receptor and CB2
knockout mice trying to understand the role of the endocannabinoid system in CDDP-induced
kidney disease. They observed that treatment with CB2 agonist HU-308 ameliorates many
CDDP-induced events like: ROS and inflammation markers; inflammatory cell infiltration and
chemokine production; leading to a marker improvement of the renal function in CDDP-
treated animals that also receive HU-308. An increase in inflammation, oxidative stress and
cell death in knockout mice CB2 -/- when compared to wild type was also observed, suggesting
the protective role of the CB2 receptor activation [44]. More recently, Mukhopaday et al. char-
acterized the partial CB2 receptor agonist LEI-101 showing promising results. The partial ago-
nist does not induce cannabimimetic in animals treated, and a considerable attenuation in
CDDP-induced nephropathy, including inflammation and oxidative stress [45].
As shown in this study, CDDP treatment increased the gene expression levels of CB2 in the
cochlea and in kidney (control) (Fig 8). This up-regulation of the inflammatory microenviron-
ment induced by the treatment with CDDP promotes the overexpression of endocannabinoid
system (increased CB2). CB2 overexpression may represent an adaptive response to control a
deregulated balance in the ear maybe trying to restore normal conditions. A deeper under-
standing of the functional role of CB2 receptor in sensory and non-sensory elements of the
cochlea may help develop therapies using CB2 as target for reducing damage to the hearing
organ. That opens a big field of possibilities to the treatment of inner ear diseases which
involves inflammation process, using drugs with non canabimimetic effects, because CB2 is the
lack of psychoactive side effects after stimulation.
Conclusions
In conclusion, evidence for the presence of cannabinoid CB2 receptor by immunohystochemis-
try and by RT-qPCR was provided. An immunolabeling of CB2 antibodies in four structures of
the adult rat cochlea was found. That was, stria vascularis, inner hair cells, auditory afferent
nerves and cell bodies of the spiral ganglion. Up-regulation of CB2 gene expression in animals
exposed to CDDP treatment was also detected, when compared with healthy animals. This fact
was partially supported by the higher immunofluorescence observed in the stria vascularis of
CB2 Receptor Expression in the Cochlea of Adult Albino Rat
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CDDP-treated animals if compared with the healthy ones. These results suggest a considerable
promising potential of CB2 receptor as a target of new treatments against CDDP-induced oto-
toxicity, and probably against other inflammatory diseases in the inner ear. Further research is
needed to determine the functionality of CB2 receptors in the organ of Corti and the potential
therapeutic role of agonists and antagonists of these receptors.
Supporting Information
S1 Fig. Detailed view of tissue sections pre adsorbed with CB2 blocking peptide. Detailed
view of the cochlea pre adsoberd with CB2 blocking peptide. No immunofluorescence was
observed in the stria vascularis (SV), the IHC or the spiral ganglion (SG) (Scale bar = 100μm).
(TIF)
S2 Fig. Measure of relative CB1 gene expression by RT-qPCR.Measure of relative CB1 gene
expression in the cochlea and kidney of healthy (control) and CDDP treated animals, respect
TBP reference. The diagrams include the mean, the standard deviation (n = 10), and the
ANOVA results (difference statistically significant respect control p<0.05).
(TIF)
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